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ABSTRACT 56 
 57 
Background. In the English pilot of primary cervical screening with high-risk human 58 
papillomavirus (HR-HPV), we exploited natural viral clearance over 24 months to minimise 59 
unnecessary referral of HR-HPV+ women with negative cytology. Three laboratories were 60 
permitted to use 16/18 genotyping to select women for referral at 12-month recall. We estimated the 61 
clinical impact of this early genotyping referral. 62 
 63 
Methods. The observed numbers of women referred to colposcopy and with detected high-grade 64 
cervical intraepithelial neoplasia (CIN2+), and of women who did not attend early recall in the three 65 
laboratories were compared with those estimated to represent a situation without an early 66 
genotyping referral. The 95% confidence intervals (CI) for the differences between the protocols 67 
were calculated by using a parametric bootstrap. 68 
 69 
Results. Amongst 127,238 screened women, 16,097 (13%) had HR-HPV infections. The 70 
genotyping protocol required 5.9% (95% CI: 4.4-7.7) additional colposcopies and led to a detection 71 
of 1.2% additional CIN2+ (95% CI: 0.6-2.0), while 2.3% (95% CI: 2.1-2.5) fewer HR-72 
HPV+/cytology- women did not attend  the early recall compared with the non-genotyping 73 
protocol. 74 
 75 
Conclusions. In a screening programme with high quality of triage cytology and high adherence to 76 
early recall,16/18 genotyping of persistent HPV infections does not substantially increase CIN2+ 77 
detection. 78 
 79 
  80 
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BACKGROUND 81 
 82 
In England, the National Health Service (NHS) has provided cervical screening since 1988 through 83 
a “call and recall” Cervical Screening Programme (CSP). Women become eligible for screening at 84 
age 25 years. Thereafter, they are recalled for cytological screening every three years until age 50 85 
years, and then five yearly until the age of 64 years. Nationwide roll-out of primary high-risk 86 
human papillomavirus (HR-HPV) screening triaged with cytology is planned to be implemented by 87 
the end of 2019. In 2013, a pilot of primary cervical screening with HR-HPV testing was set up in 88 
six large CSP laboratories, accounting for about 13% of the nationally screened population.1 89 
 90 
The aim of substituting cytology with HR-HPV testing is to achieve greater sensitivity and increase 91 
screening intervals. Because of relatively poor specificity, however, reflex cytology is required to 92 
identify those HR-HPV+ women who require colposcopy referral. In several countries including the 93 
USA and Australia, HPV 16/18 genotyping is being used at baseline to identify women with 94 
negative cytology at increased risk of underlying cervical intraepithelial neoplasia (CIN), for 95 
immediate referral.2, 3 In these cases, the decision to refer HPV 16/18 positive women is made on a 96 
single screening sample. 97 
 98 
The English pilot also recognised a potential value of HR-HPV genotyping in triage, but it was 99 
considered that implementing it in the same way as those other countries, i.e. based on a single 100 
sample, would lead to an unsustainable increase in the demand for colposcopy. Hence, women with 101 
HR-HPV infections have been managed as shown in Table 1. At baseline and at 12-month early 102 
recall, the selection of HR-HPV positive women for colposcopy relied on positive cytology, defined 103 
as borderline change in squamous or endocervical cells or worse. This is equivalent to atypical 104 
squamous cells of undetermined significance (ASCUS, and atypical glandular cells of undetermined 105 
significance, AGUS, in the Bethesda 2014 classification), or worse. Evidence of 24-month 106 
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persistence of a HR-HPV infection, regardless of concurrent cytology, also triggered referral for 107 
colposcopy. Additionally, three of the six laboratories used HPV 16/18 genotyping as a basis for 108 
more rapid referral for colposcopy in cases where there was persistent infection at the 12-month 109 
early recall in the absence of cytological abnormality. This means that a decision to refer cytology-110 
negative women to colposcopy based on 16/18 genotyping is made only after two consecutive HR-111 
HPV positive samples. 112 
 113 
Both of these triage protocols were aimed at reducing the need for colposcopy by exploiting the 114 
substantial natural clearance rates of all HR-HPV infections, including HPV 16/18.4-6 The non-115 
genotyping protocol with two early recalls within 24 months after screening, aimed to maximise the 116 
reduction in the need for colposcopy but was potentially vulnerable to the risk of non-adherence 117 
with an additional early recall. The genotyping protocol, expediting a referral of women with the 118 
most high-risk infections and reserving the second early recall for those whose infections are less 119 
likely to progress to cancer, aimed to reduce loss to follow-up at the second early recall and to 120 
maximise the detection of CIN2+ lesions requiring treatment. Hence, we evaluated the differences 121 
between the two protocols in the overall frequency of referral for colposcopy, detection of CIN2+ 122 
and CIN3+, and the loss to follow-up at early recall.  123 
 124 
MATERIALS AND METHODS 125 
 126 
The pilot 127 
 128 
The pilot started in May 2013 and the main outcomes have been described previously in detail.7 129 
Briefly, six English CSP laboratories converted around a third of their screening population from 130 
primary liquid-based cytology (LBC) to primary HR-HPV screening. Conversion was population-131 
based. The selection of administrative areas for conversion was not determined in a random process. 132 
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Rather, the laboratories considered practical issues such as maintaining a single clinical 133 
management protocol in colposcopy practices serving each administrative area. During the pilot, the 134 
population age range and recommended screening intervals remained unchanged.  135 
 136 
Screening and diagnostic tests 137 
 138 
Screening samples were taken within primary care and were collected in either SurePath (Becton 139 
Dickinson, Sparks, MD) or ThinPrep (Hologic, Marlborough, MA) LBC media. SurePath was used 140 
in three laboratories, while ThinPrep was used in the other three. In 2013-2014, two laboratories 141 
used Cobas 4800 (Roche, Rotkreuz, Switzerland, or Branchburg, NJ); two used RealTime (Abbott, 142 
Wiesbaden, Germany); and the remaining two used APTIMA (Hologic, Manchester, UK). Cobas 143 
and RealTime are HR-HPV DNA genotyping assays that report HPV 16 and HPV 18 separately 144 
from the 12 other HR-HPV genotypes, which are reported in combination. APTIMA is an HR-HPV 145 
mRNA assay detecting the 14 HR-HPV genotypes in combination.  146 
 147 
All HR-HPV assays had previously been approved for primary screening within the CSP. Triage 148 
cytology was read under routine conditions with knowledge of a HR-HPV infection, and was 149 
quality controlled to CSP standards. Colposcopy was conducted according to national clinical 150 
practice guidelines. All diagnoses reflect routine cytopathology and histopathology in the CSP.  151 
 152 
Study design 153 
 154 
The present study was designed to compare the outcomes of screening in the pilot with and without 155 
HPV 16/18 triage at the 12-month early recall. As the first screening invitation is sent at age 24.5 156 
years, we included women aged 24-64 years at the time of the screening test. Additionally, women 157 
were included if they had been screened during the first (prevalence) round of primary screening 158 
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with HR-HPV testing from the beginning of the pilot in May 2013 until December 2014 in the three 159 
Cobas or RealTime laboratories that used the HR-HPV genotyping information for the management 160 
of HR-HPV positive women (Table 1). Data on all subsequent tests and diagnoses were retrieved 161 
from the laboratories’ information systems until May 2017, which gave all women 29-49 months of 162 
follow-up after the primary screening test.  163 
 164 
Women screened in the three laboratories that did not use HR-HPV genotyping information for the 165 
management of HR-HPV positive women were not included as a comparator in this post-hoc 166 
analysis. Two of these laboratories used the APTIMA assay. Unlike DNA assays that typically 167 
detect both transient infections and those integrated into a host’s genome, APTIMA has been 168 
designed to detect (predominantly) the latter type of infections. It has indeed been observed that this 169 
assay typically detects fewer HR-HPV infections than DNA assays, which ultimately leads to lower 170 
colposcopy rates in a routine screening programme.8, 9 Consequently, using APTIMA data as a 171 
comparator would have introduced the effect of the assay’s different molecular target into the 172 
comparison of the triage protocols and hence could substantially affect analysis, particularly in 173 
terms of the number of colposcopies.  174 
 175 
The prevalence screening episode for each woman was defined as starting with the first test 176 
recorded during the pilot period, i.e. the primary (baseline) test, and closed with any early recall 177 
tests or colposcopies. If the first recorded pilot test was preceded by another test within the two 178 
prior years, or if the test’s management code identified it as a follow-up to a recent cervical 179 
abnormality, the episode was excluded from further analysis. This is because those tests were 180 
unlikely to have been taken for the purpose of primary screening. Tests were linked using each 181 
women’s unique English NHS numbers.  182 
 183 
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In this analysis, the infecting HR-HPV genotype was determined at the primary test and remained 184 
fixed even if the genotype changed by the 12-month early recall. The effect of a genotype change 185 
on the studied outcomes was addressed in a sensitivity analysis (see below). Women were included 186 
in the 16/18 category regardless of any co-infecting genotypes.  187 
 188 
Our primary endpoints were (1) the total number of colposcopies performed, (2) the number of HR-189 
HPV positive/cytology negative women not adhering to early recall, and (3) the number of detected 190 
CIN2+ lesions for each triage protocol. CIN2+ was chosen as one of the primary endpoints as this is 191 
the threshold for treatment, but the results are also presented for the more reproducible endpoint of 192 
CIN3+.10  193 
 194 
These outcomes were estimated based on aggregated observed data from the three genotyping 195 
laboratories (Table 2), and the following two sets of assumptions. Firstly, we assumed that all 196 
women would be referred as expected on the basis of their screening outcomes (Table 1). For a 197 
minority of women in the data where this did not happen (gray cells in Table 2), we assumed that 198 
they would have the same clinical outcomes as women who were referred as expected. As this was 199 
done consistently for both protocols, the calculated total numbers of colposcopies, CIN, and women 200 
not returning for early recall under the genotyping protocol differ slightly from those that were 201 
directly observed. Secondly, the 24-month outcomes in cytology-negative women persistently 202 
infected with HPV 16/18 at 12 months could not be directly observed for the non-genotyping 203 
protocol. We estimated them on the following assumptions: a) that attendance at 24-month early 204 
recall and colposcopy would be the same as that observed among women infected with other HR-205 
HPV genotypes, b) that persistence of HR-HPV infections between the 12- and 24-month early 206 
recalls would be as that observed in a fourth pilot laboratory, which reported HR-HPV genotyping 207 
data but implemented a non-genotyping triage protocol (Table 1), and c) that CIN2+ and CIN3+ 208 
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prevalent at 12-month early recall would still be detectable at 24-month early recall, i.e. that there 209 
was no excess regression or progression between the two early recalls.11  210 
 211 
Two sensitivity analyses were undertaken to assess the robustness of the findings. In the first of 212 
these, we addressed a subgroup of women with HPV 16/18 infections and persistently negative 213 
cytology at 12 months. Among these women, a relatively large proportion did not have a record of 214 
referral for colposcopy (Table 2). In the base case analysis, we assumed that this was at random. In 215 
the sensitivity analysis, we used two conventional extreme assumptions for parameters with 216 
uncertain true values, i.e. that (analysis S1a) all women in this subgroup would have attended 217 
colposcopy with CIN2+ detection doubled from the (observed) base case value; or (analysis S1b) 218 
only half of the women in this subgroup would attend with CIN2+ detection halved from the base 219 
case value. A lower CIN2+ detection could be expected, for example, in cases where HPV 16/18 220 
infection had cleared by the 12-month early recall, but the woman remains HR-HPV positive. 221 
Indeed, this situation represented about two-thirds of the women without a record of referral to 222 
colposcopy at 12 months in the observed data. In the second sensitivity analysis, persistence of 223 
infections between the 12- and 24-month early recalls in women with negative cytology and HPV 224 
16/18 infections (which played a role in estimating the number of colposcopies in the non-225 
genotyping protocol) was based on a small dataset from a single laboratory (N=98). We varied the 226 
proportion of women with persistent infections as: (analysis S2a) the lower 5% confidence limit; or 227 
(analysis S2b) the upper 95% confidence limit.  228 
 229 
Statistical analysis methods 230 
 231 
For both the number of colposcopies and the number of CIN2+ lesions detected, the relative 232 
difference was reported as the ratio between the absolute difference in the totals for the genotyping 233 
and the non-genotyping protocols (numerator) and the total number in the non-genotyping protocol 234 
  11 
(denominator). For the number of women not adhering to early recall, the total number with HR-235 
HPV positive cytology negative samples at baseline was used as the denominator. The positive 236 
predictive value (PPV) of colposcopy for CIN2+ and CIN3+ was calculated using the number of 237 
women attending colposcopy as the denominator. Detailed formulae are reported in Supplementary 238 
information. 239 
 240 
We obtained 95% confidence intervals (CI) for detection of CIN2+, number of colposcopies and 241 
loss of adherence to follow-up at the 12- and 24-month early recall using a parametric bootstrap. 242 
More precisely, following the flows in Figure 1, we sampled the numbers in each category based on 243 
the observed data in Table 2; this process was repeated 10,000 times and the empirical distributions 244 
of the resulting numbers of colposcopies, CIN2+ and CIN3+, and women not attending early recall 245 
were used to form a 95% CI. The statistical software R (version 3.4.1) was used for all analysis.12 246 
 247 
RESULTS 248 
 249 
Observed screening outcomes by HR-HPV genotype 250 
 251 
In total, 127,238 women were screened in the three genotyping laboratories in 2013-2014. Of these, 252 
16,097 (13%) had a positive HR-HPV test result, 5287 (4%) with positive and 10,810 (8%) with 253 
negative cytology (Table 2). In total, 8759 (7%) HR-HPV positive women underwent a colposcopy, 254 
leading to detection of 2859 (2%) CIN2+ and 1763 (1%) CIN3+ (Table 3 and Figure 1). These 255 
numbers include detection following the recommended management protocol, including early recall 256 
as well as any colposcopies undertaken outside the protocol. Colposcopies and CIN observed 257 
outside of the recommended protocol, for example those after an immediate referral of HR-HPV 258 
positive cytology negative women at baseline, were infrequent and were not included in further 259 
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analyses. They amounted to 310 (4%) colposcopies, 31 (1%) CIN2+, and 16 (1%) CIN3+ (Figure 260 
1).  261 
 262 
Detection of CIN2+ was highest amongst women screened at age 24-29 years: 6.6% and 4.1% for 263 
CIN2+ and CIN3+, respectively. By comparison, the numbers were 1.6% and 1.0% at 30-49, and 264 
0.5% and 0.3% at 50-64 years of age. A case of CIN2+ was detected for every three colposcopies at 265 
age 24-29 years and for every six colposcopies at age 50-64 years. For CIN3+, the numbers of 266 
colposcopies needed at these ages were four and 10 per case, respectively (data not tabulated).  267 
 268 
Half of all CIN2+ (50%, 1423/2859) and 55% (968/1763) of CIN3+ were diagnosed in women 269 
infected with HPV 16, whereas 9% (247/2859 and 153/1763) of CIN2+ and CIN3+ were detected 270 
in women with HPV 18 without HPV 16 (Table 3). Other genotypes without either HPV 16 or 18 271 
were detected in 41% (1189/2859) of CIN2+ and 36% (642/1763) of CIN3+. Amongst all 4047 272 
women infected with HPV 16, 35% (1423/4047) were ultimately diagnosed with CIN2+ and 24% 273 
(968/4047) with CIN3+. For the 1160 women infected with HPV 18, this was 21% (247/1160) and 274 
13% (153/1160), respectively, and for the remaining 10,890 women with other HR-HPV infections 275 
it was 11% (1189/10,890) and 6% (642/10,890), respectively (Table 3). 276 
 277 
During the same period, the fourth laboratory with HR-HPV DNA genotyping information, but 278 
implementing a non-genotyping triage protocol, screened 15,831 women with HR-HPV testing. Of 279 
these, 1714 (11%) had a positive HR-HPV test result, 1274 (8%) with negative and 440 (3%) with 280 
positive cytology. This was similar to the screening results in the three substantially larger 281 
laboratories included in the main analysis. Among the 98 women with HPV 16/18 infections and 282 
negative cytology persisting at 12 months, the infection persisted until 24 months in 73 (74%). This 283 
proportion was virtually constant across age groups (data not tabulated). Among women with HPV 284 
16/18 infections who attended colposcopy after the 24-month early recall, the observed PPV for 285 
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CIN2+ was 27% (19/71), with 15% (8/54) if they had negative cytology, and 65% (11/17) if they 286 
had positive cytology. 287 
 288 
Estimating the impact of the genotyping triage protocol 289 
 290 
The genotyping protocol generated detection of 2869 CIN2+ and 1769 CIN3+ resulting from 8750 291 
colposcopies among the 127,238 screened women (Table 4). More than 90% of all CIN2+ (91%, 292 
2614/2869) were detected after a referral with positive cytology at either the baseline test or at the 293 
12-month early recall. An additional 5% (133/2869) of CIN2+ were detected after a referral of HPV 294 
16/18 positive women with persistently negative cytology at 12 months, and the final 4% 295 
(123/2869) of CIN2+ were diagnosed at 24-month early recall amongst women persistently infected 296 
with other HR-HPV genotypes. This pattern was very similar for the detection of CIN3+. 297 
 298 
An estimated 1741 cytology negative women with a positive baseline HR-HPV test result did not 299 
attend the 12-month early recall. Additionally, 637 women who attended the 12-month early recall 300 
did not attend a recommended 24-month early recall. In total, we estimate that 22% (2378/10,810) 301 
of HR-HPV positive cytology negative women did not attend or complete early recall. 302 
 303 
Estimating the impact of the non-genotyping triage protocol 304 
 305 
With this protocol, a total of 2835 CIN2+ and 1751 CIN3+ would be detected as a result of 8260 306 
colposcopies among the 127,238 screened women (Table 4). Again, >90% of all high-grade CIN 307 
would be detected following positive triage cytology at baseline or at 12-month early recall. The 308 
remaining CIN2+ would be detected at the 24-month early recall for persistent HR-HPV.  309 
 310 
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Referring all persistently HR-HPV positive women with negative cytology at 12 months to an 311 
additional 24-month early recall would result in 8% (864/10,810) of women not attending, in 312 
addition to the 16% (1741/10,810) not attending the 12-month early recall. In total, we estimate that 313 
24% (2626/10,810) of HR-HPV positive cytology negative women would not have completed the 314 
recall under the non-genotyping triage protocol. 315 
 316 
PPV of a referral for colposcopy 317 
 318 
The PPVs for CIN2+ were high when a colposcopy was undertaken following a positive cytology 319 
triage test result: 41% (2135/5163) at baseline and 35% (479/1369) after the 12-month early recall 320 
(Table 4).  321 
 322 
In women infected with non-16/18 HR-HPV genotypes referred after the 24-month early recall, the 323 
PPV of a colposcopy was 10% (123/1198; Table 4). At this point, positive cytology was not used as 324 
a condition for a colposcopy. Nevertheless, the laboratories did report the cytology grade and the 325 
PPV for CIN2+ remained high, 29% (66/228), amongst women with cytological abnormalities, and 326 
much lower, 6% (51/907), amongst women who remained cytologically negative (data not 327 
tabulated; cytology of the remaining 9 out of 1144 women with a colposcopy (Table 2) was not 328 
graded). 329 
 330 
In women with HPV 16/18 positive persistently negative cytology, the PPV for CIN2+ was 13% 331 
(133/1020) at the 12-month early recall. At 24 months, the PPV for persistent HPV 16/18 332 
infections, regardless of cytology, is estimated at 18% ((221-123)/(1728-1198), Table 4). The PPV 333 
could not be reliably estimated separately by cytology but as reported earlier, it was 15% among 54 334 
cytology negative women in the fourth genotyping laboratory. 335 
 336 
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In all cases, the PPVs for CIN3+ were approximately half those for CIN2+. 337 
 338 
Comparison of the two protocols 339 
  340 
We estimate that the genotyping protocol would detect an additional 34 (95% CI: 26-43) CIN2+ 341 
and 18 (95% CI: 13-24) CIN3+ cases among the 127,238 screened women, representing 1.2% (95% 342 
CI: 0.9-1.5) of CIN2+ and 1.0% (95% CI: 0.8-1.4) of CIN3+ cases detectable by the non-343 
genotyping protocol (Table 5). It would result in 5.9% (95% CI: 5.0-6.9) more colposcopies; 8750 344 
(95% CI: 8572-8924) vs. 8260 (95% CI: 8079-8444), a difference of 490 (95% CI: 420-562). It 345 
would also result in 2.3% (95% CI: 2.1 to 2.5) fewer HR-HPV positive cytology normal women not 346 
completing their recommended early recall; 2378 (95% CI: 2283-2475) vs. 2626 (95% CI: 2520-347 
2731), a difference of 248 (95% CI: 226-270). The differences between the two protocols were very 348 
similar across all age groups (Table 5).  349 
 350 
The outcomes were not materially affected by varying the assumptions on the attendance at 351 
colposcopy and prevalence of CIN2+ in HPV 16/18 positive women with persistently negative 352 
cytology. Under the favourable scenario for the genotyping protocol (analysis S1a: a high 353 
attendance at colposcopy and a high PPV), the latter would increase the need for colposcopy by 354 
6.1% (95% CI: 5.2-7.0) and CIN2+ detection by 1.6% (95% CI: 1.3-1.9). Under the unfavourable 355 
scenario (analysis S1b: a low attendance at colposcopy and a low PPV), the estimates would be 356 
lower at 4.7% (95% CI: 3.8-5.6) and 0.3% (95% CI: 0.1-0.6), respectively. Varying the proportion 357 
of women infected with HPV 16/18 who remain HR-HPV positive by 24 months produced a range 358 
in the extra demand for colposcopy between 6.6% (analysis S2a, 95% CI: 5.6-7.6) and 5.3% 359 
(analysis S2b, 95% CI: 4.5-6.1). 360 
 361 
 362 
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DISCUSSION 363 
 364 
Using data from the English HPV pilot we estimated there would be a small increase in CIN2+ 365 
detection for HPV 16/18 genotyping compared with non-genotyping triage protocols for women 366 
with persistent HR-HPV infections and negative cytology. However, more rapid referral of 367 
persistently HPV 16/18 positive women with negative cytology would increase the number of 368 
colposcopies by 6%, which appears to be disproportionate with respect to an estimated increase in 369 
detected CIN2+ of 1%. This is a consequence of both reasonably high compliance with repeated 370 
testing in early recall observed in the pilot (close to 80%), and highly sensitive stratification of risk 371 
by cytology triage. The latter identified 75% of all CIN2+ at baseline and an additional 17% at 12-372 
month early recall, with a high PPV on both occasions of over 30%. A very small pool of CIN2+ 373 
remained to be identified solely by HR-HPV genotyping but the PPV was substantially lower at 374 
around 10%.  375 
 376 
As HPV 16/18 lesions are more likely to progress to cancer,13-15 our finding of a 1% higher 377 
detection of CIN2+ and CIN3+ with a faster referral of HPV 16/18 positive women warrants 378 
consideration. This relatively small additional increase in the number of detected CIN2+ achieved 379 
by genotyping persistent HR-HPV infections would be observed on top of the approximately 50% 380 
increase achieved in the pilot by substituting cytology with HR-HPV testing,7 and most of these 381 
cases would be detected in women below 30 years of age, when the likelihood of regression of 382 
CIN2+ is highest.16 Persistently negative cytology is often associated with early infections and 383 
lesions detectable only through HR-HPV testing have been hypothesised to be small.17 Given the 384 
long duration of progression of CIN lesions to cervical cancer,16, 18, 19 a delay of 12 months in 385 
diagnosing these cytologically negative lesions is unlikely to be associated with a significant risk of 386 
interval cancer, provided women adhere to early recall.  387 
 388 
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HPV 16/18 genotyping has been recommended for an immediate referral of HR-HPV 389 
positive/cytologically negative women in countries such as the USA2, 20 and Australia.3 In Europe, 390 
the attitude towards using genotyping in this manner has so far been more conservative,21-23 and 391 
baseline referral was not tested in the English pilot out of concern that it would lead to an 392 
unsustainable demand for colposcopy. When the switch was made from cytology to HR-HPV 393 
screening in the pilot, the demand for colposcopy increased by about 80% in the prevalence round.7 394 
Had direct referral of all HPV 16/18 positive women been recommended, we estimate that referral 395 
would increase by an additional 15-20% (Supplementary information). As expected, viral clearance 396 
however was substantial (32% of women with HPV 16/18 infections and negative cytology tested 397 
HR-HPV negative at the 12-month early recall, and a further 26% tested negative at the 24-month 398 
recall). The immediate colposcopies in women destined to clear their infections are likely to have 399 
contributed to the very high average number of colposcopies needed to detect each CIN2+ case in 400 
the ATHENA study, which evaluated a setting with immediate colposcopy of all women aged ≥25 401 
years with HPV 16/18 infections; this number was eight.11 In the English pilot, where cytologically 402 
negative women were only referred in the presence of a persistent infection, the number of 403 
colposcopies to detect a case of CIN2+ was three (8750/2869, Table 4). 404 
 405 
Birth cohorts vaccinated against HPV 16/18 in the catch-up programme did not start entering the 406 
CSP until 2015, which means that our analysis is representative of an unvaccinated population. 407 
Through cross-protection, vaccination has the potential to decrease not only the prevalence of HPV 408 
16/18 but also of certain other HR-HPV genotypes.24 As a result, the overall number of screened 409 
women who will require triage and colposcopy will decrease. The value of using genotyping for 410 
HPV 16/18 in the remaining persistent infections will probably decrease in line with the expected 411 
decrease in CIN2+ lesions associated with HPV 16/18.25  412 
 413 
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The large size and prospective protocol are key strengths of our study, as well as a population-414 
based, routine HR-HPV based screening setting using national standards and clinical guidelines, 415 
with quality assured HR-HPV testing, cytology, colposcopy, and histology. The patterns of 416 
detection of CIN2+ by genotype (Table 3) were consistent with the literature. We were limited by 417 
having access to data from the laboratories participating in the pilot; if women moved away from 418 
the catchment areas of these six laboratories, their subsequent outcomes could not be traced. 419 
Nevertheless, the completeness of follow-up was high, about 95% after a referral for a colposcopy 420 
and about 80% after a referral for an early recall (Figure 1). We could not directly observe the 421 
outcomes of a non-genotyping protocol. The resulting post hoc nature of our analysis required us to 422 
make several, albeit standard,11 assumptions on infection dynamics and the prevalence of CIN in 423 
women when managed following the non-genotyping protocol. Nonetheless, the sensitivity analyses 424 
showed that our conclusions were robust against a variety of assumptions. Additionally, using the 425 
data from the same three laboratories for both triage protocols meant that the background 426 
characteristics of the women, the catchment areas’ screening coverage, and the cytology reading 427 
practices were constant. Finally, while our study compared two defined triage protocols, it cannot 428 
provide a conclusive answer as to what the optimal triage strategy would be for English HR-HPV 429 
positive women. A full optimisation study would require a substantially different approach 430 
comparing a number of alternative strategies, varying e.g. the eligibility criteria for triage, the 431 
number of early recalls, their timing, the tests and their positivity thresholds, and any age 432 
stratification.26 This is beyond the scope of our analysis. 433 
 434 
CONCLUSION 435 
 436 
In population based screening programmes with good quality of triage cytology and where most 437 
women adhere to early recall, HPV 16/18 triage of persistently HR-HPV positive and cytologically 438 
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negative women 12 months after primary screening can add very little in terms of a clinical benefit 439 
such as additional detection of CIN2+. 440 
 441 
  442 
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Table 1. Management of women in the English pilot of primary cervical screening with HR-HPV 602 
testing. 603 
Time of testing Genotyping triage 
 
Non-genotyping triageb 
Baseline test  HR-HPV negative: routine recall at 3/5 yearsa 
HR-HPV positive/positive cytology: colposcopy 
HR-HPV positive/negative cytology: early recall at 12 months 
Early recall at 12 months HR-HPV negative: routine recall at 3/5 yearsa 
HR-HPV positive/cytology positive: colposcopy 
HPV 16/18 positive/cytology 
negative: colposcopy 
Other HR-HPV positive/cytology 
negative: early recall at 24 
months 
HR-HPV positive/cytology 
negative: early recall at 24 
months 
Early recall at 24 months HR-HPV negative: routine recall at 3/5 yearsa 
HR-HPV positive: colposcopy 
a Depending on the woman’s age. The three-year routine recall interval is used for women aged 25-49 years, whereas 604 
the five-year interval is used for women aged 50-64 years. 605 
b One of the laboratories recorded HR-HPV genotyping information using a DNA assay but did not use it for clinical 606 
management of HR-HPV positive women. 607 
 608 
 609 
 610 
 611 
  612 
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Table 2. Observed outcomes for HR-HPV positive women in the three genotyping laboratories combined. 613 
 N Yes Unknown Proportion 
Yes 
Baseline     
HR-HPV+ 127,238 16,097 258 12.7% 
Cytology+ if HR-HPV+ 16,097 5287 0 32.8% 
Had colposcopy if HR-HPV+/cytology+ after a record of referral 5287 5163 0 97.7% 
PPV of colposcopy for CIN2+ if HR-HPV+/cytology+ 5163 2135 0 41.4% 
PPV of colposcopy for CIN3+ if HR-HPV+/cytology+ 5163 1367 0 26.5% 
Early recall at 12 months (HR-HPV+/cytology- at baseline)     
Had early recall testing after a record of referral  10,810 8964 125 83.9% 
HR-HPV+  8964 5263 0 58.7% 
Cytology+ if HR-HPV+ 5263 1410 23 26.8% 
Had colposcopy if HR-HPV+/cytology+ after a record of referral 1410 1353 0 96.0% 
PPV of colposcopy for CIN2+ if HR-HPV+/cytology+ 1353 473 0 35.0% 
PPV of colposcopy for CIN3+ if HR-HPV+/cytology+ 1353 269 0 19.9% 
Cytology- if HR-HPV+ 5263 3830 23 72.8% 
HPV 16 or 18+ if HR-HPV+/cytology-  3830 1072 0 28.0% 
Had colposcopy if HPV 16 or 18+/cytology- after a record of referral 1072 789 233 94.0% 
PPV of colposcopy for CIN2+ if HPV 16 or 18+/cytology- 789 103 0 13.1% 
PPV of colposcopy for CIN3+ if HPV 16 or 18+/cytology- 789 55 0 7.0% 
Early recall at 24 months (HR-HPV other+/cytology- at baseline and HR-
HPV+/cytology- at 12-month early recall) 
    
Had early recall testing after a record of referral 2758 2091 48 77.2% 
HR-HPV+ 2091 1368 0 65.4% 
Had colposcopy after a record of referral 1368 1144 23 85.1% 
PPV of colposcopy for CIN2+ if HR-HPV+ 1144 117 0 10.2% 
PPV of colposcopy for CIN3+ if HR-HPV+ 1144 56 0 4.9% 
Early recall at 24 months (HPV 16 or 18+/cytology- at baseline and HR-HPV+/cytology- 
at 12-month early recall)a 
    
HR-HPV+ 98 73 0 74.5% 
CIN: cervical intraepithelial neoplasia. HR-HPV: high risk human papillomavirus; any of the 14 high risk genotypes detectable by the Cobas and RealTime assays unless otherwise 614 
specified. PPV: positive predictive value. 615 
  29 
Gray cells: Proportions of women who adhered to the type of clinical follow-up recommended by the protocol, calculated after exclusion of category “unknown” from the 616 
denominator (if non-zero). Where the “unknown” category was larger than zero, the value refers to women who had no record of referral to the type of follow-up that would be 617 
expected following the recommendations; for them, we assumed that their outcomes would be the same as the outcomes among women who had the correct record of referral. All 618 
other proportions are calculated using values in column “N” as the denominator, as there the “unknown” cells represent e.g. invalid testing outcomes (a normal occurrence in routine 619 
screening which leads to tailored follow-up recommendations). 620 
a Data from the fourth pilot laboratory which recorded HR-HPV genotyping information using a DNA assay but did not use it for clinical management of HR-HPV positive women. 621 
  30 
Table 3. Observed distribution of HR-HPV infections and detected CIN2+, by HR-HPV genotype 622 
and the woman’s age. 623 
  Age group 
  24-29 30-49 50-64 Total 
 N screened 23,864 
(100%) 
72,833 
(100%) 
30,541 
(100%) 
127,238 
(100%) 
 HR-HPV genotype at 
baseline      
HR-HPV 
infections 
HR-HPV+ 6709 (28%) 7646 (10%) 1742 (6%) 16,097 (13%) 
HPV 16+ 2111 (9%) 1588 (2%) 348 (1%) 4047 (3%) 
Else HPV 18+ 509 (2%) 541 (1%) 110 (<1%) 1160 (1%) 
Else other HR-HPV+ 4089 (17%) 5517 (8%) 1284 (4%) 10,890 (9%) 
Colposcopies HR-HPV+ 4013 (17%) 3890 (5%) 856 (3%) 8759 (7%) 
HPV 16+ 1649 (7%) 1125 (2%) 215 (1%) 2989 (2%) 
Else HPV 18+ 364 (2%) 325 (<1%) 61 (<1%) 750 (1%) 
Else other HR-HPV+ 2000 (8%) 2440 (3%) 580 (2%) 5020 (4%) 
CIN2+ HR-HPV+ 1579 (7%) 1133 (2%) 147 (<1%) 2859 (2%) 
HPV 16+ 899 (4%) 475 (1%) 49 (<1%) 1423 (1%) 
Else HPV 18+ 138 (1%) 95 (<1%) 14 (<1%) 247 (<1%) 
Else other HR-HPV+ 542 (2%) 563 (1%) 84 (<1%) 1189 (1%) 
CIN3+ HR-HPV+ 980 (4%) 699 (1%) 84 (<1%) 1763 (1%) 
HPV 16+ 613 (3%) 324 (<1%) 31 (<1%) 968 (1%) 
Else HPV 18+ 82 (<1%) 62 (<1%) 9 (<1%) 153 (<1%) 
Else other HR-HPV+ 285 (1%) 313 (<1%) 44 (<1%) 642 (1%) 
CIN: cervical intraepithelial neoplasia. HR-HPV: high risk human papillomavirus.  624 
 625 
 626 
 627 
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Table 4. Estimated numbers of colposcopies, high-grade CIN, and women not attending the two early recalls following the genotyping and non-628 
genotyping triage protocols, by time of testing.  629 
Time of testing Screening test 
outcome at time 
of testing 
HR-HPV genotyping protocol Non-genotyping protocol 
  Colposcopie
s 
CIN2+ 
(PPV) 
CIN3+ 
(PPV) 
Not 
attending 
early recall 
Colposcopie
s 
CIN2+ 
(PPV) 
CIN3+ 
(PPV) 
Not 
attending 
early recall 
Baseline test  HR-HPV+ and 
cyt+ 
5163 2135 (41%) 1367 (26%)  5163 2135 (41%) 1367 (26%)  
Early recall at 12 
months 
Not attending 
early recall 
   1741    1741 
HR-HPV+ and 
cyt+ 
1369 479 (35%) 272 (20%)  1369 479 (35%) 272 (20%)  
HPV 16/18+ and 
cyt- 
1020 133 (13%) 71 (7%)      
Early recall at 24 
months 
Not attending 
early recall 
   637    864 
HPV+ 1198 123 (10%) 59 (5%)  1728 221 (13%) 111 (6%)  
Total  8750 2869 (33%) 1769 (20%) 2378 8260 2835 (34%) 1751 (21%) 2626 
CIN: cervical intraepithelial neoplasia. HR-HPV: high risk human papillomavirus. PPV: positive predictive value. 630 
 631 
  632 
  32 
Table 5. Absolute and relative differences in the numbers of colposcopies, the numbers of detected CIN2+ and CIN3+, and in the numbers of women 633 
not attending early recall between the two triage protocols, by age at screening.  634 
 Absolute numbers per protocol 
 HR-HPV genotyping protocol Non-genotyping protocol 
Age (years) Colposcopies 
(95% CI) 
CIN2+  
(95% CI) 
CIN3+  
(95% CI) 
Not attending 
early recall 
(95% CI) 
Colposcopies 
(95% CI) 
CIN2+  
(95% CI) 
CIN3+  
(95% CI) 
Not attending 
early recall 
(95% CI) 
Totala 8750  
(8572-8924) 
2869  
(2762-2973) 
1769  
(1686-1851) 
2378  
(2283-2475) 
8260  
(8079-8444) 
2835  
(2730-2937) 
1751  
(1668-1832) 
2626  
(2520-2731) 
24-29 4003 
(3889-4115) 
1588 
(1510-1663) 
985 
(924-1046) 
1005 
(945-1067) 
3780 
(3658-3900) 
1566 
(1489-1640) 
973 
 (913-1033) 
1137 
(1069-1206) 
30-49 3884 
(3765-4000) 
1135 
(1068-1202) 
701 
(650-754) 
1122 
(1057-1187) 
3665 
(3543-3784) 
1123 
(1057-1189) 
694 
(644-747) 
1221 
(1150-1292) 
50-64 862 
(806-918) 
147 
(124-172) 
84 
(66-102) 
252 
(221-283) 
810 
(752-867) 
146 
(123-170) 
83 
(66-101) 
276 
(242-311) 
 635 
 Differences between the protocols 
 Absolute differences  
(genotyping protocol – non-genotyping protocol) 
Relative differences  
(vs. non-genotyping protocol) 
Age (years) Colposcopies 
(95% CI) 
CIN2+  
(95% CI) 
CIN3+  
(95% CI) 
Not attending 
early recall 
(95% CI) 
Colposcopies 
(95% CI) 
CIN2+  
(95% CI) 
CIN3+  
(95% CI) 
Not attending 
early recall 
(95% CI)b 
Totala +490  
(+420 to +562) 
+34  
(+26 to +43) 
+18  
(+13 to +24) 
-248  
(-270 to -226) 
+5.9%  
(+4.4 to +7.7) 
+1.2%  
(+0.6 to +2.0) 
+1.0%  
(+0.5 to +1.8) 
-2.3%  
(-2.5 to -2.1) 
24-29 +223 
(+174 to +277) 
+22 
(+15 to +31) 
+12 
(+7 to +17) 
-131 
(-150 to -114) 
+5.9% 
(+3.4 to +14.8) 
+1.4% 
(+0.4 to +6.2) 
+1.2% 
(+0.3 to +5.2) 
-3.2% 
(-3.6 to -2.8) 
30-49 +219 
(+174 to +269) 
+12 
(+8 to +17) 
+7 
(+4 to +11) 
-99 
(-113 to -86) 
+6.0% 
(+4.0 to +8.4) 
+1.1% 
(+0.4 to +2.0) 
+1.0% 
(+0.4 to +2.0) 
-1.8% 
(-2.1 to -1.6) 
50-64 +52 
(+33 to +74) 
+1 
(+0 to +3) 
+1 
(+0 to +2) 
-24 
(-31 to -18) 
+6.4% 
(+2.8 to +12.3) 
+0.9% 
(+0.1 to +3.0) 
+0.7% 
(+0.0 to +2.7) 
-1.8% 
(-2.3 to -1.4) 
a The totals as reported in Table 4. Sums by age differ slightly due to minor age-specific differences in completeness of follow-up and rounding. 636 
b Vs. the number of HR-HPV positive cytology negative women at baseline. 637 
  33 
FIGURE LEGENDS 638 
 639 
Figure 1. Screening outcomes including colposcopies and detection of CIN2+ outside of the 640 
recommended protocol. Screening was undertaken between May 2013 and December 2014, follow-641 
up data were retrieved until May 2017. Panel A. Women with HPV 16/18 infections at baseline. 642 
Panel B. Women with HR-HPV infections other than HPV 16/18 at baseline.  643 
 644 
  645 
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SUPPLEMENTARY INFORMATION 646 
 647 
Estimation of the additional number of colposcopies in the case of an immediate referral of all HPV 648 
16/18 positive women 649 
 650 
Total number of colposcopies in the screened population (with the genotyping protocol): 8750 651 
(Table 4) 652 
 653 
Number of HPV 16/18 positive, cytology negative women at baseline: 2914 (Figure 1) 654 
 655 
Attendance at colposcopy at baseline: 97.7% (observed for HR-HPV positive cytology positive 656 
women, Table 2) 657 
 658 
Estimated needed number of colposcopies for direct referral of HPV 16/18 positive, cytology 659 
negative women: 2846 (0.977×2914) 660 
 661 
Observed number of colposcopies in HPV 16/18 positive, cytology negative women (at any time 662 
during the early recall and including colposcopies outside of the recommended protocol): 1485 663 
(Figure 1) 664 
 665 
Difference between the estimated needed and the observed numbers: 1361 (2846-1485) 666 
 667 
Relative increase in the number of colposcopies: 16% (1361/8750) 668 
 669 
 670 
 671 
 672 
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Estimation of the numbers of detected CIN, colposcopies, and women not attending early recall in the base case analysis 673 
 674 
  675 
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Table S1. Observed data. (Note: This is the same as Table 2 in the main text, with the addition of “Code” which simplifies the calculations below. 676 
“Unknown” results were excluded from the denominators in cases of referral that deviated from the recommended management protocol.) 677 
Code Description Numerator Denominator Proportion 
 BASELINE    
N Number of women in the analysis 127,328 NR NR 
P1 HR-HPV+ 16,097 127,328 12.6% 
P2 Cytology+ if HR-HPV+ 5287 16,097 32.8% 
P3 Had colposcopy if HR-HPV+/cytology+ after a record of referral 5163 5287 97.7% 
Q1 PPV of colposcopy for CIN2+ if HR-HPV+/cytology+ 2135 5163 41.4% 
Q1b PPV of colposcopy for CIN3+ if HR-HPV+/cytology+ 1367 5163 26.5% 
 EARLY RECALL AT 12 MONTHS (HR-HPV+/cytology- at baseline)    
P4 Had testing at 12-month early recall after a record of referral 8964 10,685 83.9% 
P5 HR-HPV+  5263 8964 58.7% 
P6 Cytology+ if HR-HPV+ 1410 5263 26.8% 
P7 Had colposcopy if HR-HPV+/cytology+ after a record of referral 1353 1410 96.0% 
Q2 PPV of colposcopy for CIN2+ if HR-HPV+/cytology+ 473 1353 35.0% 
Q2b PPV of colposcopy for CIN3+ if HR-HPV+/cytology+ 269 1353 19.9% 
P6a Cytology- if HR-HPV+ 3830 5263 72.8% 
P8 HPV 16 or 18+ if HR-HPV+/cytology-  1072 3830 28.0% 
P9 Had colposcopy if HPV 16 or 18+/cytology- after a record of referral 789 839 94.0% 
Q3 PPV of colposcopy for CIN2+ if HPV 16 or 18+/cytology- 103 789 13.1% 
Q3b PPV of colposcopy for CIN3+ if HPV 16 or 18+/cytology- 55 789 7.0% 
 EARLY RECALL AT 24 MONTHS (other HR-HPV +/cytology- at baseline and HR-
HPV+/cytology- at 12-month early recall) 
   
P10 Had testing at 24-month early recall after a record of referral 2091 2710 77.2% 
P11 HR-HPV+ 1368 2091 65.4% 
P12 Had colposcopy after a record of referral 1144 1345 85.1% 
Q4 PPV of colposcopy for CIN2+ if HR-HPV+ 117 1144 10.2% 
Q4b PPV of colposcopy for CIN3+ if HR-HPV+ 56 1144 4.9% 
 EARLY RECALL AT 24 MONTHS (HPV 16 or 18+/cytology- at baseline and HR-
HPV+/cytology- at 12-month early recall) 
   
P14 HR-HPV+ 73 98 74.5% 
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Table S2. Genotyping protocol. Women with HPV 16/18 infections who remain HR-HPV+/cyt- at 12-month early recall are referred to colposcopy. 679 
Women with other HR-HPV infections who remain HR-HPV+/cyt- at 12-month early recall are referred to 24-month early recall. 680 
Time of 
testing 
Screening test outcome 
at time of testing 
Colposcopies CIN2+ CIN3+ Not attending early 
recall 
Baseline test HR-HPV+/cytology+ N*P1*P2*P3= 
127328* (16097/127328)* 
(5287/16097)* 
(5163/5287) = 5163 
N*P1*P2*P3*Q1= 
5163* (2135/5163) = 2135 
N*P1*P2*P3*Q1b= 
5163* (1367/5163) = 1367 
 
Early recall at 
12 months 
Not attending    N*P1*(1-P2)*(1-P4) = 
127328* 
(16097/127328)* (1-
(5287/16097))* (1-
8964/10685) = 1741 
 
 HR-HPV+/cytology+ N*P1*(1-
P2)*P4*P5*P6*P7= 
16097* (1-(5287/16097))* 
(8964/10685)* 
(5263/8964)* 
(1410/5263)* 
(1353/1410)= 1369 
N*P1*(1-
P2)*P4*P5*P6*P7*Q2= 
16097* (1-(5287/16097))* 
(8964/10685)* 
(5263/8964)* 
(1410/5263)* 
(1353/1410)* (473/1353)= 
479 
N*P1*(1-
P2)*P4*P5*P6*P7*Q2b= 
16097* (1-(5287/16097))* 
(8964/10685)* 
(5263/8964)* 
(1410/5263)* 
(1353/1410)* (269/1353)= 
272 
 
 HPV 16 or 18+/cytology- N*P1*(1-
P2)*P4*P5*P6a*P8*P9 = 
16097* (1-(5287/16097))* 
(8964/10685)* 
(5263/8964)* 
(3830/5263)* 
(1072/3830)* (789/839) = 
1020 
N*P1*(1-
P2)*P4*P5*P6a*P8*P9 * 
Q3 = 16097* (1-
(5287/16097))* 
(8964/10685)* 
(5263/8964)* 
(3830/5263)* 
(1072/3830)* (789/839)  * 
(103/789) = 133  
N*P1*(1-
P2)*P4*P5*P6a*P8*P9 * 
Q3b = 16097* (1-
(5287/16097))* 
(8964/10685)* 
(5263/8964)* 
(3830/5263)* 
(1072/3830)* (789/839)   * 
(55/789) = 71 
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Table S2. Continued. 682 
Time of testing Screening test outcome 
at time of testing 
Colposcopies CIN2+ CIN3+ Not attending early 
recall 
Early recall at 
24 months 
Not attending    N*P1*(1-
P2)*P4*P5*P6a*(1-
P8)*(1-P10) = 
10810* (8964/10685)* 
(5263/8964)* 
(3830/5263)* (1-
1072/3830)* (1-
2091/2710) = 637 
 HR-HPV+ N*P1*(1-
P2)*P4*P5*P6a*(1-
P8)*P10*P11*P12= 
10810* (8964/10685)* 
(5263/8964)* 
(3830/5263)* (1-
1072/3830)* 2091/2710 * 
(1368/2091) * 
(1144/1345) = 1198 
N*P1*(1-
P2)*P4*P5*P6a*(1-
P8)*P10*P11*P12*Q4 = 
10810* (8964/10685)* 
(5263/8964)* 
(3830/5263)* (1-
1072/3830)* 2091/2710 * 
(1368/2091) * (1144/1345) 
* (117/1144) = 123 
N*P1*(1-
P2)*P4*P5*P6a*(1-
P8)*P10*P11*P12*Q4b = 
10810* (8964/10685)* 
(5263/8964)* 
(3830/5263)* (1-
1072/3830)* 2091/2710 * 
(1368/2091) * (1144/1345) 
* (56/1144) = 59 
 
Total  8750 2870 1769 2378 
 683 
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Table S3. Non-genotyping protocol. All women with HR-HPV infections who remain HR-HPV+/cyt- at 12-month early recall are referred to 24-688 
month early recall (regardless of genotype). 689 
Time of 
testing 
Screening test outcome 
at time of testing 
Colposcopies CIN2+ CIN3+ Not attending early 
recall 
Baseline test HR-HPV+/cytology+ N*P1*P2*P3= 
127328* (16097/127328)* 
(5287/16097)* 
(5163/5287) = 5163 
N*P1*P2*P3*Q1= 
5163* (2135/5163) = 2135 
N*P1*P2*P3*Q1b= 
5163* (1367/5163) = 1367 
 
Early recall at 
12 months 
Not attending    N*P1*(1-P2)*(1-P4) = 
127328* (16097/127328)* 
(1-(5287/16097))* (1-
8964/10685) = 1741 
 
 HR-HPV+/cytology+ N*P1*(1-
P2)*P4*P5*P6*P7= 
16097* (1-(5287/16097))* 
(8964/10685)* 
(5263/8964)* 
(1410/5263)* 
(1353/1410)= 1369 
N*P1*(1-
P2)*P4*P5*P6*P7*Q2= 
16097* (1-(5287/16097))* 
(8964/10685)* 
(5263/8964)* 
(1410/5263)* 
(1353/1410)* (473/1353)= 
479 
N*P1*(1-
P2)*P4*P5*P6*P7*Q2b= 
16097* (1-(5287/16097))* 
(8964/10685)* 
(5263/8964)* 
(1410/5263)* 
(1353/1410)* (269/1353)= 
272 
 
Early recall at 
24 months 
Not attending    N*P1*(1-
P2)*P4*P5*P6a*(1-P10) 
= 10810* (8964/10685)* 
(5263/8964)* 
(3830/5263)* (1-
(2091/2710)) = 885 
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Table S3. Continued. 692 
Time of testing Screening test outcome 
at time of testing 
Colposcopies CIN2+ CIN3+ Not attending early 
recall 
 HR-HPV+ N*P1*(1-
P2)*P4*P5*P6a*P10*((1-
P8)*P11+P8*P14)*P12 = 
10810* (8964/10685)* 
(5263/8964)* 
(3830/5263)* 
(2091/2710)* ((1-
(1072/3830))* (1368/2091) 
+ (1072/3830)* (73/98))* 
1144/1345 = 1728 
 
HR-HPV other: 1198 
HPV 16/18: 530 
N*P1*(1-
P2)*P4*P5*P6a*(1-
P8)*P10*P11*P12*Q4  
+ N*P1*(1-
P2)*P4*P5*P6a*P8* 
P10*Q3* (1/P9)* P12= 
10810* (8964/10685)* 
(5263/8964)* 
(3830/5263)* (1-
1072/3830)* 2091/2710 * 
(1368/2091) * 
(1144/1345)* (117/1144)  
+ 10810* (8964/10685)* 
(5263/8964)* 
(3830/5263)* 
(1072/3830)* 
(2091/2710)* (103/789) * 
(839/789) * (1144/1345)= 
221  
 
HR-HPV other: 
1198*(117/1144)=123 
HPV 16/18: 
1085*(103/789)* 
(839/789)*(1144/1345) 
*(2091/2710)=  99 
N*P1*(1-
P2)*P4*P5*P6a*(1-
P8)*P10*P11*P12*Q4b  
+ N*P1*(1-
P2)*P4*P5*P6a*P8* 
P10*Q3b* (1/P9)* P12= 
10810* (8964/10685)* 
(5263/8964)* 
(3830/5263)* (1-
1072/3830)* 2091/2710 * 
(1368/2091) * 
(1144/1345)* (56/1144)  
+ 10810* (8964/10685)* 
(5263/8964)* 
(3830/5263)* 
(1072/3830)* 
(2091/2710)* (55/789) * 
(839/789) * (1144/1345)=  
111 
 
HR-HPV other: 
1198*(56/1144)=59 
HPV 16/18: 
1084*(55/789)* 
(839/789)*(1144/1345) 
*(2091/2710) =  53 
 
Total  8260 2835 1750 2626 
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